Charles Schwab Investment Management Inc. Buys 12,778 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Charles Schwab Investment Management Inc. increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 322,596 shares of the company’s stock after purchasing an additional 12,778 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.68% of Axsome Therapeutics worth $28,992,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. bought a new position in Axsome Therapeutics in the 2nd quarter worth $27,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Axsome Therapeutics in the 2nd quarter worth $47,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after purchasing an additional 318 shares during the period. Moors & Cabot Inc. bought a new position in Axsome Therapeutics in the 3rd quarter worth $200,000. Finally, Whalen Wealth Management Inc. bought a new position in Axsome Therapeutics in the 3rd quarter worth $236,000. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Trading Down 0.9 %

AXSM opened at $99.54 on Thursday. The firm has a market cap of $4.82 billion, a P/E ratio of -15.24 and a beta of 1.18. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The stock has a 50-day moving average of $92.05 and a 200 day moving average of $86.37.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the firm earned ($1.32) earnings per share. As a group, research analysts forecast that Axsome Therapeutics, Inc. will post -4.58 EPS for the current year.

Insiders Place Their Bets

In other news, Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the sale, the director now owns 10,002 shares of the company’s stock, valued at approximately $913,282.62. The trade was a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 22.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AXSM shares. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Royal Bank of Canada increased their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Robert W. Baird increased their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research note on Monday, November 25th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $130.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $124.93.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.